SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Enobia Pharma Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy